Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Spencer E. Brightman"'
Autor:
Joseph S. Dolina, Joey Lee, Spencer E. Brightman, Sara McArdle, Samantha M. Hall, Rukman R. Thota, Karla S. Zavala, Manasa Lanka, Ashmitaa Logandha Ramamoorthy Premlal, Jason A. Greenbaum, Ezra E. W. Cohen, Bjoern Peters, Stephen P. Schoenberger
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 17 (2023)
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells.
Externí odkaz:
https://doaj.org/article/2a9a0edba8ed47f8a8305d3beb9941be
Autor:
David J. Dowling, Soumik Barman, Alyson J. Smith, Francesco Borriello, Danielle Chaney, Spencer E. Brightman, Gandolina Melhem, Byron Brook, Manisha Menon, Dheeraj Soni, Simone Schüller, Karthik Siram, Etsuro Nanishi, Hélène G. Bazin, David J. Burkhart, Ofer Levy, Jay T. Evans
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract Infection is the most common cause of mortality early in life, yet the broad potential of immunization is not fully realized in this vulnerable population. Most vaccines are administered during infancy and childhood, but in some cases the fu
Externí odkaz:
https://doaj.org/article/664c1c1f13a04a379a816fa55d3b47b1
Autor:
Spencer E. Brightman, Martin S. Naradikian, Rukman R. Thota, Angelica Becker, Leslie Montero, Milad Bahmanof, Ashmitaa Logandha Ramamoorthy Premlal, Jason A. Greenbaum, Bjoern Peters, Ezra E.W. Cohen, Aaron M. Miller, Stephen P. Schoenberger
Publikováno v:
JCI Insight, Vol 8, Iss 2 (2023)
CD4+ T cells play a critical role in antitumor immunity via recognition of peptide antigens presented on MHC class II (MHC-II). Although some solid cancers can be induced to express MHC-II, the extent to which this enables direct recognition by tumor
Externí odkaz:
https://doaj.org/article/269a1b54d04f495aa248feef28743e01
Autor:
Joseph S. Dolina, Joey Lee, Spencer E. Brightman, Sara McArdle, Samantha M. Hall, Rukman R. Thota, Manasa Lanka, Ashmitaa Logandha Ramamoorthy Premlal, Jason A. Greenbaum, Ezra E.W. Cohen, Bjoern Peters, Stephen P. Schoenberger
Publikováno v:
bioRxiv
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::458ca4cdb3519a9775be1f21081abf43
https://europepmc.org/articles/PMC10187312/
https://europepmc.org/articles/PMC10187312/
Autor:
Spencer E Brightman, Angelica Becker, Rukman Thota, Martin S Naradikian, Ryan Griswold, Joseph S Dolina, Stephen P Schoenberger
Publikováno v:
The Journal of Immunology. 208:180.06-180.06
The expansion of neoantigen (NeoAg)-specific T cells often accompanies clinical responses to immunotherapies such as immune checkpoint blockade (ICB), adoptive cellular therapy (ACT), and personalized cancer vaccines (PCV), highlighting their importa